Search

Your search keyword '"Hidemi Unozawa"' showing total 3 results
Start Over Author "Hidemi Unozawa" Journal case reports in oncology
3 results on '"Hidemi Unozawa"'

1. Controlling Major Portal Vein Invasion Progression during Lenvatinib Treatment by Carbon-Ion Radiotherapy in Patients with Advanced Hepatocellular Carcinoma

Author

Ryoi Yoshida, Keisuke Koroki, Hirokazu Makishima, Sadahisa Ogasawara, Takamasa Ishino, Keita Ogawa, Miyuki Nakagawa, Kisako Fujiwara, Hidemi Unozawa, Terunao Iwanaga, Naoto Fujita, Takafumi Sakuma, Hiroaki Kanzaki, Kazufumi Kobayashi, Naoya Kanogawa, Soichiro Kiyono, Masato Nakamura, Takayuki Kondo, Tomoko Saito, Ryo Nakagawa, Eiichiro Suzuki, Yoshihiko Ooka, Shingo Nakamoto, Akinobu Tawada, Tetsuhiro Chiba, Makoto Arai, Takashi Kaneko, Masaru Wakatsuki, Jun Kato, Hiroshi Tsuji, and Naoya Kato

Subjects
carbon-ion radiotherapy, hepatocellular carcinoma, macrovascular invasion, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Macrovascular invasion (MVI), including portal vein tumor thrombosis (PVTT), is strongly associated with poor prognosis in patients with hepatocellular carcinoma (HCC). While recommended standard treatment for patients with advanced HCC is systemic therapy, various treatment approaches, including resection, transarterial chemoembolization, and radiation, have been empirically suggested to improve prognosis by eliminating or controlling MVI. Herein, we report our experience of a case with advanced HCC where MVI was controlled by carbon-ion radiotherapy (CIRT) while on systemic therapy, resulting in a prolonged survival. A female patient with HCC in her early 60s had multiple intrahepatic lesions (maximum 60 mm in diameter) with PVTT. The PVTT of this patient had reached the main trunk of the portal vein despite the use of lenvatinib. The other intrahepatic lesions of the patient, except PVTT, had been controlled by lenvatinib. Therefore, hoping to control PVTT, we attempted CIRT. The patient resumed lenvatinib therapy after the irradiation. During lenvatinib re-treatment, no evident progression of PVTT was observed in the patient.

Published
2021
Full Text
View/download PDF

2. Controlling Major Portal Vein Invasion Progression during Lenvatinib Treatment by Carbon-Ion Radiotherapy in Patients with Advanced Hepatocellular Carcinoma

Author

Hiroaki Kanzaki, Sadahisa Ogasawara, Jun Kato, Makoto Arai, Takamasa Ishino, Naoya Kato, Hirokazu Makishima, Masato Nakamura, Takayuki Kondo, K. Fujiwara, Masaru Wakatsuki, Shingo Nakamoto, Miyuki Nakagawa, Keita Ogawa, Ryoi Yoshida, Tomoko Saito, Kazufumi Kobayashi, Hiroshi Tsuji, Takafumi Sakuma, Eiichiro Suzuki, Akinobu Tawada, Naoto Fujita, Tetsuhiro Chiba, Keisuke Koroki, Naoya Kanogawa, Terunao Iwanaga, Ryo Nakagawa, Yoshihiko Ooka, Takashi Kaneko, Hidemi Unozawa, and Soichiro Kiyono

Subjects
medicine.medical_specialty, business.industry, medicine.medical_treatment, Standard treatment, Portal vein, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, carbon-ion radiotherapy, hepatocellular carcinoma, medicine.disease, Thrombosis, Radiation therapy, chemistry.chemical_compound, Oncology, chemistry, Hepatocellular carcinoma, medicine, macrovascular invasion, Carbon Ion Radiotherapy, In patient, Radiology, business, Lenvatinib, RC254-282
Abstract

Macrovascular invasion (MVI), including portal vein tumor thrombosis (PVTT), is strongly associated with poor prognosis in patients with hepatocellular carcinoma (HCC). While recommended standard treatment for patients with advanced HCC is systemic therapy, various treatment approaches, including resection, transarterial chemoembolization, and radiation, have been empirically suggested to improve prognosis by eliminating or controlling MVI. Herein, we report our experience of a case with advanced HCC where MVI was controlled by carbon-ion radiotherapy (CIRT) while on systemic therapy, resulting in a prolonged survival. A female patient with HCC in her early 60s had multiple intrahepatic lesions (maximum 60 mm in diameter) with PVTT. The PVTT of this patient had reached the main trunk of the portal vein despite the use of lenvatinib. The other intrahepatic lesions of the patient, except PVTT, had been controlled by lenvatinib. Therefore, hoping to control PVTT, we attempted CIRT. The patient resumed lenvatinib therapy after the irradiation. During lenvatinib re-treatment, no evident progression of PVTT was observed in the patient.

Published
2021

3. Controlling Major Portal Vein Invasion Progression during Lenvatinib Treatment by Carbon-Ion Radiotherapy in Patients with Advanced Hepatocellular Carcinoma

Author

Yoshida, Ryoi, Koroki, Keisuke, Makishima, Hirokazu, Ogasawara, Sadahisa, Ishino, Takamasa, Ogawa, Keita, Nakagawa, Miyuki, Fujiwara, Kisako, Hidemi Unozawa, Iwanaga, Terunao, Fujita, Naoto, Sakuma, Takafumi, Kanzaki, Hiroaki, Kobayashi, Kazufumi, Kanogawa, Naoya, Kiyono, Soichiro, Nakamura, Masato, Kondo, Takayuki, Saito, Tomoko, Nakagawa, Ryo, Suzuk, Eiichiro, Ooka, Yoshihiko, Nakamoto, Shingo, Tawada, Akinobu, Chiba, Tetsuhiro, Arai, Makoto, Kaneko, Takashi, Wakatsuki, Masaru, Kato, Jun, Tsuji, Hiroshi, Kato, Naoya, Hirokazu, Makishima, Keita, Ogawa, Naoto, Fujita, Naoya, Kanogawa, Tomoko, Saitou, Takashi, Kaneko, Masaru, Wakatsuki, and Hiroshi, Tsuji

Abstract

Macrovascular invasion (MVI), including portal vein tumor thrombosis (PVTT), is strongly associated with poor prognosis in patients with hepatocellular carcinoma (HCC). While recommended standard treatment for patients with advanced HCC is systemic therapy, various treatment approaches, including resection, transarterial chemoembolization, and radiation, have been empirically suggested to improve prognosis by eliminating or controlling MVI. Herein, we report our experience of a case with advanced HCC where MVI was controlled by carbon-ion radiotherapy (CIRT) while on systemic therapy, resulting in a prolonged survival. A female patient with HCC in her early 60s had multiple intrahepatic lesions (maximum 60 mm in diameter) with PVTT. The PVTT of this patient had reached the main trunk of the portal vein despite the use of lenvatinib. The other intrahepatic lesions of the patient, except PVTT, had been controlled by lenvatinib. Therefore, hoping to control PVTT, we attempted CIRT. The patient resumed lenvatinib therapy after the irradiation. During lenvatinib re-treatment, no evident progression of PVTT was observed in the patient.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results